# Women Excluded: The Gender Gap in Drug Trials Systemic exclusion of women from clinical research leads to higher drug side effects. - **Source:** [Discovery](https://brifing.si/source/fab2bb9c-affd-4609-8ac8-7ab7dc697d4f) - **Published:** 2026-08-10 - **Original article:** - **On Brifing:** https://brifing.si/s/1c07c2d1-f3b6-415f-b1cd-00e486407382 ## Exclusion of Women from Clinical Trials Dr. Ella Hubber discovered she was working exclusively with male mice while researching type 1 diabetes treatment. This revealed how modern medicine isn't equally designed for all. Historically, women have been systematically excluded from clinical trials. This practice has resulted in insufficient research on drug effects in women. Biological differences play crucial roles in drug metabolism, yet these factors are often overlooked in male-dominated studies. ## Impact of Biological Differences Male and female bodies respond differently to medications due to factors like hormonal variations, body fat percentage, and enzyme activity. However, most research focuses on male subjects, ignoring these critical differences. This oversight leads to higher rates of adverse drug reactions in women. For instance, certain sleep medications remain active longer in women's systems compared to men's. These variations can significantly affect treatment efficacy and safety profiles. ## Historical Context and Current Status In the 1970s, the U.S. banned women from clinical trials, a restriction only lifted in 1993. Despite this change, male bias persists in medical research. Many contemporary studies still predominantly use male subjects, perpetuating gender inequality in drug development. While awareness has grown in recent years, progress remains slow. Women's representation in trials still falls short of equitable levels, continuing to impact healthcare outcomes. ## Side Effects on Women's Health Women experience 50-70% more adverse drug reactions than men, particularly with cardiovascular medications and antidepressants. Some side effects become severe enough to require hospitalization, adding financial burden to healthcare systems. These reactions also negatively impact treatment adherence among female patients. Long-term consequences include reduced quality of life and increased healthcare utilization. The economic and personal costs of this imbalance are substantial and preventable. ## Growing Awareness and Reform Efforts Recent years have seen increased recognition of this issue within scientific communities. Some countries have enacted laws mandating gender balance in clinical research. Researchers are incorporating sex-based analysis more frequently in data evaluation. However, the pharmaceutical industry requires more fundamental changes to address systemic biases. Dedicated research programs focusing on women's health need expansion. Medical education must also prioritize teaching about sex and gender differences in pharmacology. ## Pharmaceutical Industry's Responsibility Drug companies must increase female participation in clinical trials. Sex-specific data analysis should become standard in drug development processes. Regulatory agencies need to implement stricter oversight mechanisms for gender representation. Companies should be required to report sex differences in research outcomes transparently. Without these changes, medications unsafe for women will continue reaching the market, perpetuating health disparities. ## Role of Patients and Physicians Female patients should monitor medication side effects carefully. Physicians must consider sex differences when prescribing treatments. Patients participating in research should question gender representation in trial designs. Health literacy programs need to address this knowledge gap. Collaborative efforts between patients and doctors can drive demand for industry reform. Public pressure may accelerate necessary changes in research practices. ## Future of Gender-Equal Medicine Equal representation of women in clinical research is crucial for medicine's future. Sex-specific approaches form the foundation of personalized treatments. Revising research methodologies will enable development of safer medications for all. These changes will improve health outcomes not just for women, but for entire populations. Establishing scientific equity must become a cornerstone of medical ethics. A more inclusive healthcare system is achievable for future generations. ## Sources covering this story - http://www.bbc.co.uk/programmes/w3ct8jsr — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._